Several recent findings have revealed that targeting of cell cycle reentry and (or) progression may provide an opportunity for the therapeutic intervention of Alzheimer’s disease (AD). FOXG1 has been shown to play important roles in pattern formation, cell proliferation, and cell specification. Thus far, the roles of FoxG1 and its involvement in AD are largely unknown.
Objective:
Our study aimed to explore the intervention effect of FOXG1 on AD pathology and its potential mechanism with a particular focus on cell cycle regulation.
Methods:
We investigated the association of Foxg1 gene variants with AD-like behavioral deficits, p21 expression, neuronal apoptosis, and amyloid-β (Aβ) aggregate formation; we further determined whether targeting FOXG1-regulated cell cycle has therapeutic potential in AD.
Results:
Paralleling AD-like behavioral abnormalities, neuronal apoptosis, and Aβ deposits, a significant reduction in the expression of FOXG1 was observed in APP/PS1 mice at 6 months of age. Using the APP/PS1;Foxg1fl/fl-CreAAV mouse line, we found that FOXG1 potentially antagonized cell cycle reentry by negatively regulating the levels of p21-activated kinase (PAK3). By reducing p21cip1-mediated arrest at the G2 stage and regulating cyclin A1- and cyclin B-dependent progression patterns of the cell cycle, FOXG1 blocked neuronal apoptosis and Aβ deposition.
Conclusion:
These results indicate that FOXG1 contributes to the regulation of the neuronal cell cycle, thereby affecting brain abnormalities in AD. An elevation of the FOXG1 level, either pharmacologically or through other means, could present a therapeutic strategy for AD.
GranaX, ReddyEP (1995) Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene11, 211–219.
2.
McPhieDL, CoopersmithR, Hines-PeraltaA, ChenY, IvinsKJ, ManlySP, KozlowskiMR, NeveKA, NeveRL (2003) DNA synthesis and neuronal apoptosis caused by familial Alzheimer disease mutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3. J Neurosci23, 6914–6927.
3.
NeveRL, McPhieDL (2006) The cell cycle as a therapeutic target for Alzheimer’s disease. Pharmacol Ther111, 99–113.
4.
YangY, GeldmacherDS, HerrupK (2001) DNA replication precedes neuronal cell death in Alzheimer’s disease. J Neurosci21, 2661–2668.
5.
McSheaA, WahlAF, SmithMA (1999) Re-entry into the cell cycle: A mechanism for neurodegeneration in Alzheimer disease. Med Hypotheses52, 525–527.
6.
ZekanowskiC, WojdaU (2009) Aneuploidy, chromosomal missegregation, and cell cycle reentry in Alzheimer’s disease. Acta Neurobiol Exp69, 232–253.
7.
ArendtT (2003) Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: The ‘Dr. Jekyll and Mr. Hyde concept’ of Alzheimer’s disease or the yin and yang of neuroplasticity. Prog Neurobiol71, 83–248.
8.
SharmaR, KumarD, JhaNK, JhaSK, AmbastaRK, KumarP (2017) Re-expression of cell cycle markers in aged neurons and muscles: Whether cells should divide or die?Biochim Biophys Acta Mol Basis Dis1863, 324–336.
9.
WebberKM, CasadesusG, ZhuX, ObrenovichME, AtwoodCS, PerryG, BowenRL, SmithMA (2006) The cell cycle and hormonal fluxes in Alzheimer disease: A novel therapeutic target. Curr Pharm Des12, 691–697.
ChenD, WangC, LiM, SheX, YuanY, ChenH, ZhangW, ZhaoC (2019) Loss of Foxg1 impairs the development of cortical SST-interneurons leading to abnormal emotional and social behaviors. Cereb Cortex29, 3666–3682.
16.
WangJ, SongHR, GuoMN, MaSF, YunQ, LiuWJ, HuYM, ZhuYQ (2020) PGC-1alpha regulate critical period plasticity via gene x environment interaction in the developmental trajectory to schizophrenia. Biochem Biophys Res Commun525, 989–996.
17.
KlugmannM, SymesCW, LeichtleinCB, KlaussnerBK, DunningJ, FongD, YoungD, DuringMJ (2005) AAV-mediated hippocampal expression of short and long Homer 1 proteins differentially affect cognition and seizure activity in adult rats. Mol Cell Neurosci28, 347–360.
18.
von JonquieresG, MersmannN, KlugmannCB, HarastaAE, LutzB, TeahanO, HousleyGD, FrohlichD, Kramer-AlbersEM, KlugmannM (2013) Glial promoter selectivity following AAV-delivery to the immature brain. PLoS One8, e65646.
KoyanoT, NambaM, KobayashiT, NakakuniK, NakanoD, FukushimaM, NishiyamaA, MatsuyamaM (2019) The p21 dependent G2 arrest of the cell cycle in epithelial tubular cells links to the early stage of renal fibrosis. Sci Rep9, 12059.
30.
RainaAK, ZhuX, SmithMA (2004) Alzheimer’s disease and the cell cycle. Acta Neurobiol Exp (Wars)64, 107–112.
31.
LanctotKL, HerrmannN, YauKK, KhanLR, LiuBA, LouLouMM, EinarsonTR (2003) Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: A meta-analysis. CMAJ169, 557–564.
32.
MaY, JunGR, ZhangX, ChungJ, NajAC, ChenY, BellenguezC, Hamilton-NelsonK, MartinER, KunkleBW, BisJC, DebetteS, DeStefanoAL, FornageM, NicolasG, van DuijnC, BennettDA, De JagerPL, MayeuxR, HainesJL, Pericak-VanceMA, SeshadriS, LambertJC, SchellenbergGD, LunettaKL, FarrerLA (2019) Analysis of whole-exome sequencing data for Alzheimer disease stratified by APOE genotype. JAMA Neurol76, 1099–1108.
33.
PolitisPK, ThomaidouD, MatsasR (2008) Coordination of cell cycle exit and differentiation of neuronal progenitors. Cell Cycle7, 691–697.
34.
ZhuX, RainaAK, RottkampCA, AlievG, PerryG, BouxH, SmithMA (2001) Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer’s disease. J Neurochem76, 435–441.
35.
NagyZ (2007) The dysregulation of the cell cycle and the diagnosis of Alzheimer’s disease. Biochim Biophys Acta1772, 402–408.
36.
NagyZ, EsiriMM, SmithAD (1998) The cell division cycle and the pathophysiology of Alzheimer’s disease. Neuroscience87, 731–739.
